Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 12/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 3/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16522812 | 0.76 | NOS1 (0.42) | METAP2AXLNOS1DYRK1AIDO1 | |
| SCHEMBL30852842 | 0.76 | NOS1 (0.42) | METAP2AXLNOS1DYRK1AIDO1 | |
| SCHEMBL35211500 | 0.74 | METAP2 (0.39) | METAP2TRPA1TRPM8TRPV1NOS1 | |
| SCHEMBL2630775 | 0.73 | IDO1 (0.44) | METAP2NOS1DYRK1AIDO1TDO2 | |
| SCHEMBL17518917 | 0.69 | METAP2 (0.53) | METAP2TRPA1TRPM8TRPV1NOS1 | |
| SCHEMBL30959600 | 0.68 | AXL (0.47) | METAP2AXLCYP1A2TRPA1TRPM8 | |
| SCHEMBL2630729 | 0.67 | NT5E (0.30) | — | |
| SCHEMBL30997139 | 0.67 | AXL (0.46) | METAP2AXLCYP1A2TRPA1TRPM8 | |
| SCHEMBL10850431 | 0.67 | NT5E (0.42) | METAP2TRPA1TRPM8TRPV1NOS1 | |
| SCHEMBL5660020 | 0.66 | NT5E (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130267513-A1 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2013-10-10 | — | — | US | disclosed |
| EP-2569293-A1 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 | Medical Research Council Technology (GB) | 2013-03-20 | — | — | EP | disclosed |
| WO-2011141756-A1 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267513-A1 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 | LRRK2, PARK7, GRK3 | METAP2 4123/4885AXL 962/4885CYP1A2 3622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.